FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreatic Cancer|Melanoma
Interventions: DRUG: FATE-NK100|DRUG: Cetuximab|DRUG: Trastuzumab
Sponsor: Fate Therapeutics